Human Immunology News 4.30 August 2, 2016 | |
| |
TOP STORYPre-B acute lymphoblastic leukemia originates from a committed pre-B cell or an earlier progenitor, with potential to reprogram into other hematopoietic lineages. Scientists report changes in lineage markers including myeloid conversion in patients following CD19 chimeric antigen receptor (CAR) therapy. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists showed that primary in vitro stimulation of CD45RA-selected CD4 T cells of stem-cell donors with 10/10 HLA-matched AML blasts results in expansion of cytolytic T-lymphocytes that almost all recognize HLA-DPB1 mismatch alleles, which clinically occur in up to 80% of donor-patient pairs. [Leukemia] Abstract The effectiveness of human T-cells targeted with full-length follicle-stimulating hormone in vivo was determined against a panel of patient-derived xenografts. [Clin Cancer Res] Abstract | Press Release Clinical-Grade Human Multipotent Adult Progenitor Cells Block CD8+ Cytotoxic T Lymphocytes The interaction between MultiStem and CD8+ cytotoxic T lymphocytes (CTLs) was addressed for the first time. In an in vitro setting, the immunogenicity of MultiStem, the susceptibility of MultiStem toward CTL-mediated lysis, and its effects on CTL function were investigated. [Stem Cells Transl Med] Abstract Phenotypic and Functional Characteristics of IL-21-Expressing CD8+ T Cells in Human Nasal Polyps Researchers analyzed cell markers, cytokine expression and transcription factors in IL-21-expressing CD8+ T cells in polyp tissues of nasal polyp patients. [Sci Rep] Full Article The authors found that SHIP is indistinguishably recruited to the plasma membrane after BCR stimulation with or without FcγRIIB coligation in human cell lines and primary cells. [J Immunol] Abstract The authors demonstrated mutually exclusive use of exon 1 and 2 amongst 16 novel THEMIS isoforms. They also showed inverse correlation between THEMIS expression in human CD4+ T-cells and dosage of the multiple sclerosis risk allele at rs13204742, driven by reduced expression of exon 1- containing isoforms. [PLoS One] Full Article Researchers investigated the expression, localization and role of GLS1 and GLUL in naïve and activated human CD4+ T cells stimulated through the CD3 and CD28 receptors under normoxia and hypoxia. [PLoS One] Full Article The authors tested the hypothesis that uncontrolled expansion of diabetogenic T cells in patients occurs, resulting from failure to activate apoptosis. They compared function, transcriptome and epigenetic regulation thereof in relation with fate upon repeated exposure to islet-autoantigen of islet autoreactive T cells from healthy and type 1 diabetic donors with identical islet epitope specificity and HLA-A2 restriction. [Genes Immunity] Abstract Investigators compared the presence of regulatory T cells in the local lung cancer environment versus systemic immune response based on the examination of bronchoalveolar lavage fluid and peripheral blood from the same patient. [Hum Immunol] Abstract Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News. | |
| |
REVIEWSThe Human Intestinal B-Cell Response The intestinal immune system is chronically challenged by a huge plethora of antigens derived from the lumen. B-cell responses in organized gut-associated lymphoid tissues and regional lymph nodes that are driven chronically by gut antigens generate the largest population of antibody-producing cells in the body: the gut lamina propria plasma cells. [Mucosal Immunol] Abstract Visit our reviews page to see a complete list of reviews in the human immunology research field. | |
| |
INDUSTRY NEWSRegeneron Pharmaceuticals, Inc. and Adicet Bio, Inc. announced a collaboration and licensing agreement to develop next-generation engineered immune cell therapeutics. The companies plan to engineer immune cells with fully human chimeric antigen receptors and T-cell receptors directed to disease-specific cell surface antigens in order to enable the precise engagement and killing of tumor cells. [Regeneron Pharmaceuticals, Inc.] Press Release Neon Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug application for its lead program, NEO-PV-01. [Neon Therapeutics] Press Release The Cancer Research Institute will bestow its highest honors on three scientists who have made fundamental contributions to the fields of immunology and cancer immunology. [The Cancer Research Institute] Press Release | |
| |
EVENTSNEW Adoptive T-Cell Therapy Summit 2016 Visit our events page to see a complete list of events in the human immunology community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – CRISPR/Cas9 Screens in Immune Cells (Wellcome Trust Sanger Institute) Research Associate – Immunology and Cell Separation (STEMCELL Technologies Inc.) Technical Sales Representative (STEMCELL Technologies Inc.) Research Technologist – Cell Separation (STEMCELL Technologies Inc.) Scientist – Bioengineering (STEMCELL Technologies Inc.) Senior Scientist – Immunology and Cell Separation (STEMCELL Technologies Inc.) Postdoctoral Research Associate – Immunology (Benaroya Research Institute at Virginia Mason) Postdoctoral Position – Immunology (Ludwig-Maximilians-Universität) Postdoctoral Fellow – Cancer Biology and Cancer Immunology (Fox Chase Cancer Center) Postdoctoral Position – Mucosal immunology (KU Leuven) Tenure Track Positions – Chemical Immunology (Institute for Chemical Immunology) Postdoctoral Scientist – Immune Focused In Vitro Research (Celentyx Ltd) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Human Immunology News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|